Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) is a leading biopharmaceutical company headquartered in San Francisco, California, with additional manufacturing operations in Huntsville, Alabama. The company specializes in developing novel therapeutics using its advanced polymer conjugate chemistry technology platform. Nektar has a robust, wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology, alongside a portfolio of approved partnered medicines.
Oncology: Nektar is actively working on activating the body's natural tumor-fighting mechanisms. Several immuno-oncology drug candidates are being studied in clinical trials for various cancer indications. One of the most notable candidates is NKTR-255, which targets the IL-15 pathway to enhance anti-tumor immune response by boosting the proliferation and persistence of NK and CD8+ T cells.
Immunology: The company is dedicated to addressing imbalances in the immune system to restore self-tolerance and achieve immune homeostasis. Rezpegaldesleukin (REZPEG), a novel T regulatory cell biologic, is being evaluated in Phase 2b studies for atopic dermatitis and alopecia areata. This biologic aims to dampen inflammatory responses and restore immune balance.
Virology: Nektar is exploring the use of selective immuno-modulators to combat viral infections by modulating the immune system's response. The company's technology has enabled the development of nine approved products for partners, including some of the top biopharmaceutical companies.
Recent Achievements: Recent highlights include the initiation of a Phase 2b study for REZPEG in severe to very severe alopecia areata, and a poster presentation at the 65th American Society of Hematology Annual Meeting showcasing preclinical data on NKTR-255. These studies underscore Nektar's commitment to advancing innovative treatments for critical health conditions.
Financial Condition: On March 4, 2024, Nektar announced a securities purchase agreement with TCGX for a $30 million private placement, bolstering its financial position and extending its cash runway into the third quarter of 2026. Additionally, the company reported ongoing clinical trials and collaborations, including studies with CAR-T cell therapies and PD-1 immunotherapies, further enhancing its pipeline.
For more information about Nektar Therapeutics and its pioneering drug development programs, visit Nektar's official website.
Nektar Therapeutics (NKTR) will release its financial results for Q4 and the year ended December 31, 2021, on February 28, 2022, after U.S. market close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss the results. Investors can access the live audio webcast through Nektar's website, with replays available until March 28, 2022. The company focuses on R&D in oncology, immunology, and virology, with a pipeline of investigational drugs and partnered medicines.
Nektar Therapeutics (Nasdaq: NKTR) CEO Howard Robin will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. The event will be accessible via a webcast linked on Nektar's Investor Events Calendar and will remain available for replay until February 11, 2022. Nektar is a biopharmaceutical company based in San Francisco, focusing on R&D in oncology, immunology, and virology.
Nektar Therapeutics (NASDAQ: NKTR) announced promising preliminary results from a Phase 1b proof-of-concept study of NKTR-358, a novel T regulatory cell stimulator, in patients with moderate-to-severe atopic dermatitis. The study showed a dose-dependent reduction in EASI scores, with a 70% maximum reduction at the 24 ug/kg dose after 12 weeks. Sustained disease control was observed for at least 6 months post-treatment. The results suggest NKTR-358's potential to differentiate from current treatments, supporting plans for a Phase 2 study by Eli Lilly.
Exelixis, Inc. has initiated the dose-escalation stage of the STELLAR-002 trial, exploring XL092, a next-generation tyrosine kinase inhibitor, in combination with immuno-oncology therapies for advanced cancers. Collaborating with Bristol-Myers Squibb and Nektar Therapeutics, the trial aims to assess safety and efficacy among patients with advanced solid tumors. The study will focus on renal cell carcinoma, urothelial carcinoma, and metastatic castration-resistant prostate cancer, with primary endpoints including objective response rates and progression-free survival.
Nektar Therapeutics (NASDAQ:NKTR) presented promising data for its investigational drug NKTR-255 at the 63rd American Society of Hematology Annual Meeting. Initial results from a Phase 1 study show NKTR-255 was well tolerated among patients with relapsed/refractory hematologic malignancies, with 53% achieving disease stabilization. The drug demonstrated potential to enhance CAR-T cell persistence and trigger immune response. Ongoing studies aim to investigate NKTR-255 in combination with current therapies for non-Hodgkin's lymphoma and multiple myeloma, with further results anticipated in 2022.
Nektar Therapeutics (NASDAQ: NKTR) announced upcoming presentations for its cytokine immuno-oncology programs at major conferences. Data for the IL-2 agonist, bempegaldesleukin (BEMPEG), will be showcased at the 2021 ESMO-IO Congress in Geneva from December 8-11. Additionally, the 63rd ASH Annual Meeting in Atlanta will feature presentations for the IL-15 agonist, NKTR-255, on December 11-14. The company will also host a webcast for analysts and investors on December 6 to discuss the findings.
Nektar Therapeutics (NASDAQ: NKTR) announced the appointment of Diana M. Brainard, M.D., as an independent director to its Board of Directors, enhancing its leadership with her extensive experience in healthcare and academia. President Howard W. Robin expressed confidence that her background in clinical development and regulatory strategy will positively impact Nektar's pipeline of immune-oncology and immunology candidates. Dr. Brainard currently serves as CEO of AlloVir and has a history of successful initiatives in manufacturing and business strategy.
Nektar Therapeutics (NKTR) presented data on its immuno-oncology pipeline at the 2021 SITC Annual Meeting. Key highlights include early clinical results from a Phase 1/2 study showing NKTR-255 combined with cetuximab is well tolerated, with 1 patient achieving a confirmed partial response and 5 with stable disease. Additionally, translational data from bempegaldesleukin (BEMPEG) combined with nivolumab and NKTR-262 were presented, suggesting potential efficacy. Nektar plans further studies as dose escalation continues.
Nektar Therapeutics (NASDAQ:NKTR) is set to host a webcast analyst and investor conference call on November 12, 2021, at 12:00 p.m. EST. The event will feature cancer specialists, including Dr. Mehmet Altan and Dr. Alan Tan, and will coincide with the publication of the NKTR-255 poster (Abstract #957) during the 2021 Society for Immunotherapy of Cancer Annual Meeting in Washington, D.C. The call will include insights into ongoing clinical studies and findings on NKTR-255 and its combination therapies.
Nektar Therapeutics (NKTR) reported Q3 2021 financial results, revealing revenues of $24.9 million, down from $30.0 million in Q3 2020. Year-to-date revenues were $76.9 million, significantly lower than $129.5 million for the same period last year, primarily due to $50 million in milestone recognition in 2020. Total operating expenses rose to $138.5 million, while the net loss for Q3 was $129.7 million or $0.70 per share, compared to $108.6 million or $0.61 per share in Q3 2020. The company emphasized progress in clinical trials and upcoming data releases.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
What does Nektar Therapeutics specialize in?
What are some of Nektar's recent achievements?
What is NKTR-255?
What is REZPEG?
Who are Nektar's partners?
Where is Nektar Therapeutics headquartered?
What is the financial outlook for Nektar?
What are the main focus areas for Nektar in oncology?
How does Nektar address immunology?